Evaluation of Hepcidin Isoforms in Hemodialysis Patients by a Proteomic Approach Based on SELDI-TOF MS

<table>Reduction Ratio (%) of serum hepcidin-25 (a) and hepcidin-20 (b) by the different hemodialysis techniques. (*Statistically significant <svg height="11.25" id="M33" style="vertical-align:-0.30096pt" version="1.1" viewbox="0 0 48.337502 11.25" width="48.337502" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.25)">
<g transform="translate(72,-63)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
<tspan style="font-size: 12.50px; " x="10.890113" y="0">&lt;</tspan>
<tspan style="font-size: 12.50px; " x="22.930502" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="26.056252" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="32.307751" y="0">5</tspan>
</text>
</g>
</g>
</svg>).</table>

BioMed Research International

fig4

Figure 4

Figure 4: Evaluation of Hepcidin Isoforms in Hemodialysis Patients by a Proteomic Approach Based on SELDI-TOF MS 